A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01304524
Recruitment Status : Completed
First Posted : February 25, 2011
Last Update Posted : September 7, 2018
Information provided by (Responsible Party):
Inovio Pharmaceuticals